BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas

European Journal of Endocrinology

Volumn 165, Issue 3, 2011, Pages 455-463

  Durante, Cosimo ^a   Tallini, Giovanni ^b   Puxeddu, Efisio ^c   Sponziello, Marialuisa ^a   Moretti, Sonia ^c   Ligorio, Claudia ^b   Cavaliere, Antonio ^c   Rhoden, Kerry J ^b   Verrienti, Antonella ^a   Maranghi, Marianna ^a   Giacomelli, Laura ^a   Russo, Diego ^d   Filetti, Sebastiano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMINE; MESSENGER RNA; MOLECULAR MARKER; NEUROPILIN 1; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; VALINE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; TUMOR MARKER; VASCULOTROPIN; ANGIOGENIC PROTEIN; BRAF PROTEIN, HUMAN; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ARTICLE; CELL LINE; DRUG RESPONSE; DRUG SCREENING; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH VESSEL; MAJOR CLINICAL STUDY; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID CELL; THYROID PAPILLARY CARCINOMA; B TYPE RAF KINASE GENE; CANCER RISK; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; GENE INDUCTION; GENE SILENCING; MUTATOR GENE; NEUROPILIN 1 GENE; PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA GENE; RECEPTOR GENE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 GENE; ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; DRUG ANTAGONISM; FEMALE; GENETICS; MALE; METABOLISM; MICROCIRCULATION; MIDDLE AGED; MUTATION; THYROID GLAND; THYROID TUMOR; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; MIDDLE AGED; MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; THYROID GLAND; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051706001     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0283     Document Type: Article

References (40)

1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL & Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214. (doi:10.1089/thy.2009.0110)
2. Arturi F, Russo D, Giuffrida D, SchlumbergerM & Filetti S. Sodium-iodide symporter (NIS) gene expression in lymph node metastases of papillary thyroid carcinomas. European Journal of Endocrinology 2000 143 623-627. (doi:10.1530/eje.0.1430623)
3. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F & Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 2006 91 2892-2899. (doi:10.1210/jc.2005-2838)
4. Schlumberger M, Lacroix L, Russo D, Filetti S & Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nature Clinical Practice. Endocrinology & Metabolism 2007 3 260-269. (doi:10.1038/ncpendmet0449)
5. Russo D, Damante G, Puxeddu E, Durante C & Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. Journal of Molecular Endocrinology 2011 46 R73-R81. (doi:10.1530/JME-10-0150)
6. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ & Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008 26 4714-4719. (doi:10.1200/JCO.2008.16.3279)
7. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M & Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009 27 1675-1684. (doi:10.1200/JCO.2008.18.2717)
8. Kerbel RS. Tumor angiogenesis. New England Journal of Medicine 2008 358 2039-2049. (doi:10.1056/NEJMra0706596)
9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 2004 25 581-611. (doi:10.1210/er.2003-0027)
10. de la Torre NG, Buley I, Wass JA & Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocrine-Related Cancer 2006 13 931-944. (doi:10.1677/erc.1. 01210)
11. Jebreel A, England J, Bedford K, Murphy J, Karsai L & Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. International Journal of Experimental Pathology 2007 88 271-277. (doi:10.1111/j.1365-2613. 2007.00533.x)
12. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE & Clark OH. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. Journal of Clinical Endocrinology and Metabolism 1997 82 3741-3747. (doi:10.1210/jc.82.11.3741)
13. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM & Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000 10 349-357. (doi:10.1089/thy.2000.10.349)
14. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, Leclère J, Duprez A & Weryha G. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2001 86 656-658. (doi:10.1210/jc.86.2.656)
15. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL & Tuttle RM. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001 129 552-558. (doi:10.1067/msy.2001.112592)
16. Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S & Leite V. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. European Journal of Endocrinology 2005 153 701-709. (doi:10.1530/eje.1.02009)
17. V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2006 91 3667-3670. (doi:10.1210/jc.2005-2836)
18. Wang Y, Ji M, Wang W, Miao Z, Hou P, Chen X, Xu F, Zhu G, Sun X, Li Y, Condouris S, Liu D, Yan S, Pan J & Xing M. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocrine-Related Cancer 2008 15 183-190. (doi:10.1677/ERC-07-0182)
19. de Araujo-Filho VJ, Alves VA, de Castro IV, Lourenço SV, Cernea CR, Branda&tild;o LG & Ferraz AR. Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid 2009 19 1233-1237. (doi:10.1089/thy.2008.0179)
20. Tuttle RM, Fleisher M, Francis GL & Robbins RJ. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. Journal of Clinical Endocrinology and Metabolism 2002 87 1737-1742. (doi:10.1210/jc.87.4. 1737)
21. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S & Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. Journal of Clinical Endocrinology and Metabolism 2007 92 2840-2843. (doi:10.1210/jc.2006-2707)
22. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ & Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. New England Journal of Medicine 2008 359 31-42. (doi:10.1056/NEJMoa075853)
23. American Joint Committee on Cancer. Thyroid. In AJCC Cancer Staging Manual, 6 edn, pp 77-87. Eds FL Greene, DL Page, ID Fleming, AG Fritz, CM Balch, DG Haller & MMorrow, New York, Berlin, and Heidelberg: Springer-Verlag, 2002.
24. V600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Research 2005 65 2465-2473. (doi:10.1158/0008-5472.CAN-04-3314)
25. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC & Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism 2008 93 4331-4341. (doi:10.1210/jc.2008-1102)
26. Sponziello ML, Bruno R, Durante C, D'Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S & Russo D. Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Hormone and Metabolic Research 2011 43 22-25. (doi:10.1055/s-0030-1265226)
27. -ΔΔCT method. Methods 2001 25 402-408. (doi:10.1006/meth.2001.1262)
28. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML & Fusco A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clinical Cancer Research 1998 4 287-294. (Pubitemid 28122740)
29. Sauter B, Foedinger D, Sterniczky B, Wolff K & Rappersberger K. Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells: differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. Journal of Histochemistry and Cytochemistry 1998 46 165-176. (doi:10.1177/ 002215549804600205)
30. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK & Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. American Journal of Pathology 2005 166 913-921. (doi:10.1016/S0002-9440(10)62311-5)
31. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. American Journal of Pathology 1995 147 9-19.
32. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A & Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 2005 115 1068-1081. (doi:10.1172/JCI22758)
33. V600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Research 2006 66 6521-6529. (doi:10.1158/0008-5472.CAN-06- 0739)
34. V600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006 147 5699-5707. (doi:10.1210/en. 2006-0400)
35. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007 148 948-953. (doi:10.1210/en.2006-0927)
36. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F & Elisei R. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data froma multicentric Italian study and review of the literature. Endocrine-Related Cancer 2006 13 455-464. (doi:10.1677/erc.1.01086)
37. Puxeddu E, Durante C, Avenia N, Filetti S & Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. Trends in Endocrinology and Metabolism 2008 19 138-145. (doi:10.1016/j.tem.2007.12.003)
38. Nikiel B, Chekan M, Jarzab M & Lange D. Endogenous avidin biotin activity (EABA) in thyroid pathology: immunohistochemical study. Thyroid Research 2009 2 5. (doi:10.1186/1756-6614-2-5)
39. Hayat MA. Problems in antigen retrieval. In Microscopy, Immunohistochemistry, and Antigen Retrieval Methods: For Light and Electron Microscopy. Edn 1, Chapter 5, pp 98-100. Ed Springer, New York: Kluwer Academic/Plenum Publishers, 2002.
40. Hall FT, Freeman JL, Asa SL, Jackson DG & Beasley NJ. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Archives of Otolaryngology - Head and Neck Surgery 2003 129 716-719. (doi:10.1001/archotol. 129.7.716)